Takeda Pharmaceutical Company Limited (LON:0A87)

Market Cap	33.41B
Revenue (ttm)	22.67B
Net Income (ttm)	692.70M
Shares Out	n/a
EPS (ttm)	0.43
PE Ratio	48.23
Forward PE	n/a
Dividend	0.44 (3.10%)
Ex-Dividend Date	Mar 31, 2025

Volume	902
Average Volume	2,033
Open	14.06
Previous Close	n/a
Day's Range	14.06 - 14.06
52-Week Range	12.82 - 15.38
Beta	n/a
RSI	51.12
Earnings Date	Jul 30, 2025

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A87

Financial Performance

In 2024, LON:0A87's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY